IFN-α2

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
IFN-α2 (Human)

GtoPdb Ligand ID: 4960

Synonyms: IFN-alpha-2 | interferon alpha-2 | Roferon A®

IFN-α2 is an approved drug (FDA (1989))

Compound class: Endogenous peptide in human, mouse or rat

Comment: IFN-α2 is a type I IFN. The sequence of the recombinant peptide used clinically and known as interferon alfa-2a, is identical to that of human IFN-α2. Interferon α-2a has anti-viral, immunomodulatory and antineoplastic actions.
Pegylated IFN-α-2a is on the World Health Organization's List of Essential Medicines.

Species: Human

References
1. FDA. Orphan Products Designation Search Page. Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drugs Administration- Orphan Products Designation Search Page, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm?StartRow=1&EndRow=25
2. FDA. Orphan Products Designation Search Page (Natural human lymphoblastoid interferon-alpha). Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drug Administration- Orphan Drug Designations and Approvals, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
3. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. (2015) Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab. Protein Sci, 24 (9): 1440-50. [PMID:26099203]
4. Witte A, Williams D, Cardarelli JM, King D, Passmore D. (2010) Anti-interferon Alpha Antibodies. Patent number: US7741449. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 22/06/2010.

References

1. FDA.
Orphan Products Designation Search Page.
Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drugs Administration- Orphan Products Designation Search Page, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm?StartRow=1&EndRow=25

2. FDA.
Orphan Products Designation Search Page (Natural human lymphoblastoid interferon-alpha).
Accessed on 04/07/2016. Modified on 04/07/2016. US Food and Drug Administration- Orphan Drug Designations and Approvals, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm

3. Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. (2015)
Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.
Protein Sci, 24 (9): 1440-50. [PMID:26099203]

4. Witte A, Williams D, Cardarelli JM, King D, Passmore D. (2010)
Anti-interferon Alpha Antibodies.
Patent number: US7741449. Assignee: Medarex, Inc.. Priority date: 10/12/2003. Publication date: 22/06/2010.